MDAI - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Spectral AI, Inc.

Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Devin Sullivan of the Equity Group. Please go ahead.

Devin Sullivan

Nick. you, Thank everyone. Good afternoon, for Quarter joining AI's you for us Results Conference Second Financial XXXX Call. Thank Spectral

Our speakers Officer. for Officer; today will be Peter Capone, company's and Carlson, the Chief Financial Vince Chief Executive

everyone When during XXXX, Before will, I'd the intends, words Litigation States these statements. plans, outlook. variations words statements be financial or projected, company's harbor expects, meaning that plans, expressions the negative we these made and Private forecasts, provision estimates, such including Reform the forward-looking the this forward-looking words believes, expressions strategy, within initiatives the objectives, like remind or Securities may used statements of or begin, constitute statements similar of should are of discussions, versions identify call, anticipates, regarding that to intended may, seek, of certain of during and Act safe United to the

results number actual uncertainties, those forward-looking are outside the conditions outcomes not guarantees in of which cause of control other unknown the differ materially risks, to performance, or discussed future forward-looking and are company's a that and or assumptions statements. factors, many known could These results involve important and from statements of

could events the filings actual contained and risks identify that statements. should the reliance the those with certainties address cautioned on foregoing the Factors such, of uncertainties Risk materially forward-looking place section risks These As filings SEC. important company's statements. described Investors results investors cause and in not and to carefully other to any are from the and and undue consider forward-looking differ factors other in the

to ahead. like Executive AI's now Officer. I over Pete, said, that to Spectral turn go would Chief the please Carlson, With Pete call

Peter Carlson

wound appreciate to our had progress afternoon, revenues for in System quarter, second Devin, assessment everyone. are AI-driven us We financial pleased quarter the making say proprietary you you, in today Thank and strong advancing results platform conference we call. technology. significant good joining and DeepView second I'm our We

improve providing as technology company economic while health operational outcomes and product to for system. believe is a the focus achieve commercialization tangible care a across Our will that we benefits

creating tool a reflects accuracy spent which is DeepView than and diagnostic assessment. the XX DeepView the $XXX delivery that medical government the partner have more our accurate validate awards, clinical executives, technology clinicians believe supports and that more AI-driven The and the only We of and million informed of successful from commitment non-dilutive predictive utility of institutions. of than we a of dedicated fast, development trials group engineers, wound years a multiple platform,

from evolution commercial stage will with of this with indication of an in commercialization first company along sales to The business our Kingdom technology for manifest the development year. burn DeepView exclusively the United our product later clinical development

be a this revenues to XXXX submission our modest, these System in DeepView success will initial achievement as the the significant prove long-term the be to impact landmark planned validation and to commercial FDA of of by platform provided Although should commercial the with technology. respect the

quarters. several recent discussing expect next time achievements our catalysts and the over some we spend highlighting the I'll

deploy commercialize, to allow of These advance the burn Kingdom, train We In and how clinical AI of institutions States, understanding for the deployments initial taking preparing the the facilities units. device addition future the of enhances data real-world in familiarity these gain AI the and burn commercialization, of with steps us increased term, over XXXX important February as of availability algorithm better at that UKCA for authorization. following commercial longer partner establish devices we receipt in the in provide to and a a U.K. United commercial United we to other the presence a DeepView DeepView X total geographies. of to across are deployed

desired our announce of the at subject U.S. portion complete to pleased this count of Burn for Pivotal study total XX% enrollment to and burn have enrollment Study I'm that expect for shortly. we our centers exceeded

Pivotal can wound sites operational of limitations less introduced pivotal most believe the Enrollment quickly exceeds it million of treated. different of longer in the the in total largest are DeepView the the burn It into EDs to that Inversely, That benefits, the studies than FDA as to will DeepView than the patients for continue generally the for number XX the limited clinical injured -- would number periods in As across and To on trials one was burn Burn surgeons. accurately comprised severely to trial be address reminder, United more of more used staff. those before nation practice. Why a designed departments of X,XXX, is generally, XXX% or to gap. economic care expanded is XXX having any AI-driven month the allowing now We just that end, and specialists be and are sites on final a both in Study study? burn XXX validate are to last and we of will this single burn focused pediatric XXXX triaged ever the yield particular efficiencies that care conducted we a have structural the EDs the they can we algorithm In XXXX. more that enrollment and by workflow U.S. States emergency enroll, United This some by burn centers. of U.S. conducting people, significant EDs. DeepView clinical achieved States. seek sites than to department XXX approximately care enrollment emergency at centers just beginning number there in centers be X EDs and centers how of reflects and burn burns while approval

burn who the that patients most are believe where those such the heal for that likely time treatment can unnecessary we we deciding should to specialist surgeries DeepView assessed, also avoid TBSA documentation area initially who see their trauma adding technology uniform emergency In estimate a or body centers, a patients assessment At predictive to measurements. standardized surgery can by burn accelerate patient. avoiding burn departments to on DeepView At a unnecessary offered DeepView for or transfers require center while own. surface when provides wounds confidence both imaging and scenarios, units while are total in

of Reflecting XXXX. the enrollment U.S. the use for into half centers, have in classification for We in burn the departments, would to the deployment submit anticipate immediately emergency entry remaining After primary expect believe burn will early clinical centers we deploying completed DeepView this approval centers, in centers AI de by trial use burn leverage the into request in of result to where burn those in the we health commercialization to U.S. submit request in XXX(k) promote U.S. momentum for emergency for into in in where the receipt adoption novo plan a classification We technology XXXX. the we point we this would care sequence first burn novo work. of the expert that begin with commercialization the DeepView technology the de departments, of followed will use for of of the system.

opportunity Australia based burn of treatment the an Ltd., will providers in such the leader. rollout U.K. we the understanding with MOU, an support Spectral Special commercial market multiple the a deploy for our eventual and of most have to Under in presence evaluations experiences. with to application recent Beyond Scheme world's respected goal geographies through lay the one establish solutions X Access allowing of established for our to as U.S. and devices and an or a memorandum groundwork DeepView on Australian PolyNovo the of SAS AI to PolyNovo clinical

DeepView the how to our M, be applied development $XXX,XXX extend Significant DeepView version contract of M of $X great in beyond to technology benefit of that inked both To current making new the end, just the AI is and Snapshot this than cart-based year, algorithm potential we is combat total developing a indications can our of DeepView over Snapshot handheld we progress assessment capture intended the at a our burn valued for technology for more wound a focus. the years setting. are brings Earlier that that image in and military million. that DeepView

prioritized serve for to integral be DeepView a that Snapshot applications of believe DeepView burn so We first by injuries our be can health unit. wound use care Snapshot potential is evacuation. care other M the that quick of mobile designed beyond more the part providing military and more assessment and Battlefield extend an providers with triage responders process accurate M well that severe to soldiers with

meeting, scientific attendees. presenting the sharing we This abstract of Use We Combat System our Military Department Handheld Health at DeepView's the XXXX with Symposium. upcoming Assessment for the Field is Burn forward look event Device Defense's progress an of Advancing foremost Research are Military to titled and

and contract of let's helpful FDA million in from to The a us XXXX centers of of future emergency and XXXX, XXXX. in indication. clinical This XXXX, X later be the than will is of timing to the feature in for commence enhancement, with million BARDA, through BioShield phases, $XX our in payments assessing expect approximately across support cash select awarded timing government nearly from for first Specific to BARDA. of Project under approval of estimated phase from bit of the no which devices which first base burn the September and discussions departments processes to primarily half remaining base received phase amounts $XX of Through our we we talk first validation the quarter deployment months take cash the Now million about have $XX flows. these U.S. phases revenues burn contracts, U.S. next are the are the procurement, of

to the awarded Spectral announce turning Total Spectral [ paid include government $XXX more agencies, date, items X. since tech were million discuss Microcap couple added U.S. over stock government under almost was million. A BARDA ] to before to has $XXX and has company our the approximate Russell million things to contracts In very some awarded summary, other XXXX Index to which to to over XXXX, $XXX since contracts happy these and Vince. We totaling July that effective to contracts.

continued patents XX from our property and intellectual granted moat to strengthen We increased XX from XX. our --

XX additional pending an worldwide. have applications also patent We

alternatives to health newly property formed Spectral IP-focused and continue leverage IP, those to acquisition our care assess subsidiary potential to identify assets. intellectual we for regarding Finally,

associated no the a this from resources require and limited additional subsidiary As the company. capital activities reminder, management with

operating company involved subsidiary. be Additionally, in will assets no this the core of

the conversation turn over now Vince. I'll to

Vincent Capone

you as this I of well. will issued operating release additional With focus thank contains filed XX-Q today. our key and Pete, details Thanks, metrics. which with and for the highlights SEC We results, my this mind, select financial joining afternoon remarks in our afternoon, all us our we that and press on

the which in BioShield second This Gross quarter to which rose accounted revenue the as We under of XX% due the contract margin to for quarter most to are last XXXX. of $X.X second of of R&D of the pleased our quarter September increased to million higher reimbursement compared level was operating contract, XXXX. $X.X Project the XX.X% XX.X% second from year rate an throughout previously Project noted, reflects revenue BARDA BARDA as the BARDA to also Burn to BioShield from in in in company the under last contract, rose report the in awarded reimbursement that million the activity rate year. growth II

ended With headcount year's administrative during $X.X as revenue XXXX in percentage second million compared to last and quarter second said, the from of XXXX of decreased rose to administrative XXX% XX% periods. higher million, the $X.X expenses as to quarter. general the second comparable research and in of quarter expense a during other Non-revenue-generating for reflecting decrease that General expenses approximately in comparable approximately for months by XX, related X XXXX, to ended as the XXXX. months same XXXX. to the $XXX,XXX million compared was the decreased offset an activities in $X.X increase XXXX, to X June development This June by the compared as and XX, period period of administrative

during compared debt payments as in and the costs quarter convertible reflecting second were the from second borrowing-related was quarter year. of no approximately of with quarter. the new issued due of XXXX up the Other expenses standby equity XXXX, of $XXX,XXX agreement the expensed to notes in for primarily to the costs announced issuance were March quarter last our costs This from that $XXX,XXX second

million million trimmed to share $X.X a in to per pleased we we're our $X.X to loss of share. Lastly, loss the as second net per quarter quarter or compared year last net for of XX% or $X.XX the announce

of XX,XXX,XXX XXXX, As June had shares XX, we outstanding.

Moving the to sheet. now balance

June million newly $X.X owned up As totaled formed Spectral Cash cash of XX, cash the XX, June company's at XX, XXXX. from XXXX, XXXX, included equivalents on in IP. $X.X subsidiary, wholly and December million, $XXX,XXX

agreement enhanced common The our call, a million a $XX investment agreement on stock purchase our a $XX.X entering capital of bank long-only standby has by into completing with agreement an last equity discussed included and equity of total purchase capacity access to a purchase million As we investor. standby advances. that prepaid with

XXXX, million company XX, XX, The June the was net received these million $X.X prepaid of the As in July a advances. of on final XXXX. advance by $X.X received company

draws As a reminder, advances are company. of million above any at total the additional the discretion of $XX.X sole prepaid the

governmental M. of our the For expected device, funding of This million we increase XX% BARDA $XX approximately we XXXX, work BioShield an as reported reflects in guidance of in from Snapshot XXXX. Project contract reiterating the additional development DeepView continued are our million, handheld well revenue our on the growth as about $XX.X

not any begin Our U.K. may guidance are our burn that indication for that the contributions the any of the this other year System from reflect contributions to expected System. sales in does commercialization DeepView from DeepView of result or the later

With and turn the you, over to that, Pete. thank conversation we'll back I

Peter Carlson

you, Vince. Thank

progress with Nick, you. future. very half the year open let's the about our of We call for and first through our Thank are are the questions. optimistic pleased

Operator

[Operator from BTIG. Instructions] Ryan The Zimmerman first question with comes

Ryan Zimmerman

guys. to of Congrats on I a questions, just start, couple Maybe your progress. have

from to just First, -- guidance. related

I let's the a first want from time, So move half the last I more if relative little regarding you BARDA suggested confirm think just to development million. second second and into the et year Vince, bit second on the we that guys maybe your to for the $XX based half. cetera, expectation timing revenue the half, as still say, the half that's milestones, of just the

Vincent Capone

nice really half to revenue see second ramping Ryan, BARDA Yes, we up trials you. clinical to grow. to the continue in talk our the Yes, as continue to

million the clinical here, trial half can on this sit the we that market, $XX.X feel we to excited reiterate as million continue sitting is half we our think to confident revenue I of $XX in XXXX, in of with first second development for we're year. the and something

Ryan Zimmerman

kind commercial you talked And think -- burn but you about helpful. then, about talked about you as Pete, going a presence little this like thoughts burn standpoint size either does a you of building kind market? that look after bit, as or of the Very market, a stage, commercial cost early at around that about to Okay. What standpoint that presence. that think in from a you this targeting or U.S. any

Peter Carlson

talk. to good Ryan,

you of in We we'll even get the the people, it of as have We And the be -- partner in need into service department. a particularly sort burn a of in really only need -- devices but to commercial this we centers but the the deployment service device As we will moderate, not department resources, emergency look where that onetime large is market. the a that's or the to to the a volume build distribution still out is operation field transaction. burn a have market, frankly, to our BARDA. centers, some do emergency

sales commercial with So to the we see do build not large force. need operation a significant

Ryan Zimmerman

Clearly determination prioritizing Very me do like. trial wound Okay. current burns patients, guys And is then one The helpful. data? what And sneak in. right the U.S., to in that reached just looks now. the more wound with XXX for it let what over you

time U.S. help patients. line completing understand be us will potentially XXX in the DFU Just on those based what the for

Peter Carlson

go going and set that at get focused full internally the the the indication quarter this while this Yes. a finalizing a diabetic fourth study, the through very last we as burn ulcers? patients it to Is we trial. probably to about to here et from Is are And how the the what a final look standpoint. set FDA, given trial. do And strategic and us talked we the how of to so path going that's kind indication -- -- of the want we approach the data And wound where the best what does stands The how on foot set forward work particularly the asset we bed today. results a our -- relates cetera? -- preparedness, in assessing of wounds, insights application the readout data of feel market tells and what data we'll early forward, reimbursement we're to broader we indication significant what's is do, trial that look it with that assessment the have particular like best

to you near coming burn mean a the centers of indication think broader only meaningful economics the would majority from vast burn we at but department. basis, When not look see our the that as emergency into we it midterm, the about the on penetration

relative out change you very significant longer-term as years. So to get our indication, X that second not X a in it's timing for -- as plans look you to

Operator

question Markets. The with next Northland from comes Carl Capital Byrnes

Carl Byrnes

Congratulations might terms bit of the But that's the deployments. terms the progress know well. U.K.? by million year cited in guidance been contribution. U.K. further that deployments end can in not in here. for maybe looking of on And you drill $XX my of answered you I know the little on be included had you questions a in of have as What Most X I you the

Peter Carlson

there, we're Carl. to as going going some on. that here Good to those -- we X the more -- convert revenues. these to are Thanks, talk. to X important commercial of What's goes deployments standpoint a year From be deployment deployments possible or into is

or to yet neat not are next the the impact also rollout. we have coming pretty opportunity a But further -- ready week. We up

in that device care (sic) I indications, from the podium, next be an already share presence other annual help the opportunities there from for and their U.K. burn first to a of to burn environment U.K. because -- interest significant each and ourselves, that there, International care or burn I burn the we're but Society health And Society sites I of a see with Burns attendance care going our as is conference. working wound with participants. providers excited that of number U.S. Injuries of the burn one surgeons attendance. have care International indication has across to in these care attendees also visit will Burn output the in are to think, significant health has inform burn mentioned The get [ we ] We'll of the are really including from there a and with output. going others. steps It's be the

Carl Byrnes

Got it. might other months? here. any follow-up we similar Do to the next And the -- X just Great. see That's partnerships in to XX there in you helpful. or Australia alliances in then are that another works PolyNovo

Peter Carlson

open-ended say, that We about That's question. but a both all talking opportunity. yes, The to very domestically and elsewhere is we be we'll be would appreciate that's able certainly and with others, are answer that hope one to don't any current continue to significant new with other geographies. well make geographies to commitment the as want have way partnerships in though. partners or No, both I announced, in as like yes,

Operator

Next Wainwright. question comes H.C. from Ramakanth with RK

Swayampakula Ramakanth

A couple here. of quick questions

be in terms folks possible here to is helping in to the the U.S.? U.K. And trying data just reimbursement you any that So publish the in it designing used understand. U.S. your it deployment, of commercialization? regarding of some the for can of U.K. the for is How also,

Peter Carlson

ask to feedback. have for thoughts getting particularly excited very his Jeremiah constructive give this clinicians. work and leveraging thoughts, or the experience. then early And and positive been share We're to with you Okay. and receiving his question. Thanks I'll already about we're I'll opportunity my

staff also So we strategy, our rollout cetera. what it's support sets only et types how it's skill performing need, not of we informing rollout, and commercial but performance, device

give Jeremiah let me additional you Let thoughts. his

Jeremiah Sparks

Pete. you, Thank

and echo for the evaluations would the and these start I constructive understand Pete start giving U.K. the would So in us said. what feedback, commercialization the us ability how helping is we very The device to U.S. good just process in do and better us feedback

beyond results publications, the get payers question about et as so on us looking that's something help reimbursement. phase your that with to clinicians with definitely information to they work can out and we're will move that to the in their these evaluation U.S., we publish to the that cetera, Specifically that

Swayampakula Ramakanth

in trying expectations do of in into one, expansion. label pediatric a of the How then instance? the and terms getting the expansion you pediatrics in label U.S., of And study, much patients how of I'm understand expansion the market included market inclusion terms to also get the first label -- in by just in the

Peter Carlson

look pediatrics. you about when go And RK. burn are that at it Thanks, the for than admissions of even generally -- environment, The situations burn it can at XX% be pediatrics actually in -- -- you times. can higher

to able focus a been make working our us BARDA be included of serve that to always in We with pediatrics we it's community. So to in sure studies. want

of technologies, is we patients. is the several imaging. Doppler requires and its image as and U.K. thus U.S., as sedation minutes pediatric the something One laser often the called in today well the in capture that of takes see this to exists technology That

with a having our benefit in X a You is imagine a the where child see where opportunity in comes in, young the sit capture second we to This to useful still. than image burn burns. and be of really place can less pain

it opportunity. that know expands market don't I the

in market. it the and acceptance I the enhances willingness think

we in So community. that in tool, speed. think the the the similar opportunity, our I we of the the our market, the numbers with pediatric use capabilities are burn and of about the measurement talked both of have portion quantity generally ease expectation tell in thus patient interest the would help you things deployment will to a increase have But help of pediatric included penetration and

Swayampakula Ramakanth

will all in trying also, to all And a start it One This started initially How in product? centers do to commercializing you the place of take in your about I think for last regarding question you me. couple Australian market. long Australia. is think talking

such commercialization ]? Australian let's the that process? is the authorities the let's is start initiating application product [ giving the, part that of So commercializing Or process say, part you of

Peter Carlson

something And can want that. to that? -- has do do Jeremiah if we we'll let you add, Vince, take him to

Vincent Capone

hear to from Yes, good RK, you.

away, respect with for the into a get think I us PolyNovo, program of X good the to machines. rollout potential to we're access probably have help their there tangent work at have doing to through least have program but to hospital's us access is months in get committees XX also That's with a special with just ensure board would say, to that I work introducing everybody good on each through special we ethics device as not to our there. the is

at a So as may partnership, initial the it starting than -- we look so a it's more a XX-month of the commercial really to it XXXX, that and opportunity partnership more beyond present there them, period so with gathering data XXXX. into subsequent that

Operator

from The John question next Zacks. Instructions] [Operator Vandermosten with comes

John Vandermosten

of approved and you what deployed. approved? the DeepView I want the handheld M. Snapshot you'll and of some have first developing with By getting explore are And all, have that's I that some time and challenges, of to the I the challenges already ready, that guess guess, for opportunities that

incremental approval? are version the challenges mobile product So get the the what to for of

Peter Carlson

Good Certainly, the John, to challenge. it's miniaturization Pete. talk. is the

you is into size large -- of with X difficult in X are household to sturdy, there and easy cameras -- affordable, materials. images manipulate see And on a So iron. those captured to image portable something can that cameras, version, environments to is of a out capture current the with get challenge. referred device the the our and sort some in this it our as The of I website and cart-based associated separate

bigger, cameras about various to in see get and while really a ways much and ultimately than and talk team push vendors with is smaller And capture And to doing aren't maintaining challenge, it's they've not the cameras hear it image team the the the the the that that's quality been into smaller perspective. worked pin. smaller if amazing

so are the in data these technology. satellite -- sort either set high-resolution And device to or X have high-quality, the the accessible there again, both And of by ability capturing is we images. cameras then

aspects are device those miniaturization. the the So of couple engineering-type of

Yes.

more through and process, of being not these will with Sort one these easier my or have remarks, believe uses assessed. that's is a about frame of get like be And have once be a that talked be indications predicates it because in approval the thing. frame, the we shorter time regulatory same will shorter prepared other time I aspect a easier, will we narrow the XXX(k)

is So the would the miniature the that it the statistics. consistent and wound of their has the AI that handheld or what do predictive we look the capture version to with to ability image demonstrate sort same the demonstrate and -- assessment make performance is of

John Vandermosten

required do And the regulatory bit. like -- look Will XXX-some-odd machine? side that regulatory you what what there Okay. that a for you And things little mentioned pathway does of be to a regulatory patient trial? worked a Or the from on just sure the handheld works of the nod are well you terms just scale on large getting making that as regulators? what scale in

Peter Carlson

military. -- think when of me of also can or foot one private pleased working done, be to other you a diabetic shareholders our and we're like on field in it behalf more that an We're with do is have technology I ulcer the that neat take might in and indications to chronic is care a to practice is developing supporting in you we that We ways multiple offices. think proud we the path. in let -- a normal other really very step in opportunity very acceptance agencies that there's But say, get we device technology. and think and pleased commercialize the into commercial particularly DoD path, Again, outstanding this the twofold that. One the think regulatory is these use the back. help wound

is technology, to capabilities to them have we device think, For the access going of be to more affordable, very this smaller with powerful.

of a do is large need the has it a the significantly to but a technology. cart-based bit little similar to technology to to do think to yes, be So able we We that demonstrate be trial? enough trial working don't

but size We that, haven't, this point, XXX tried certainly I don't would it at be this like think to trial. patients current

John Vandermosten

Okay. the the of potential the question I areas market on the is guess And market. of and size last

handheld how these might a center this? ambulances to you of guys And size? of them. for it might and size be use a Is burn are that other market of said ED of is think I support the compared getting items. of it market it? the any areas What your that really maybe that? appropriate larger? to grants mean some have And place good maybe sense obviously, you're fraction to military place Or is kind just equal? I it Is be

Peter Carlson

here at get it and A it where be points one these the also. a of round various units let hospital burn complex in my a in multiple situation several smaller there center. into areas site? is or a thoughts, emergency give Jeremiah the let So have couple to you Part cart-based say, of high-volume as And would want how device out. department we -- place would me I'll large as, might like practice well many devices of

opens about dealing like it that not situations other far we've what out And with opportunities. talked foot the wound as The also are ulcers clinics like some private our diabetic in care there up wound the practices this is a chronic market of material but practices. with private the X,XXX is X,XXX-plus only as

where in be like thinking was an that take And -- you those be cost think no we where so were maybe on areas justify situation. there and And would ambulance? effective, The a about. would Level the carried it this something then factors being helpful in to that's if somebody Yes, And that's get so have ambulance numbers you of could if it other they very would directly X trauma -- it the center. volume ambulance types the into burn centers. maybe about that

So his let Jeremiah add me let thoughts.

Jeremiah Sparks

we well. site assess indication we're types I And wound this, very said think types service. that looking it at, physician Pete even when There's There's the outpatient at of we're No, both Pete. the inpatient. basically, and looking what offices. Thanks, potentially of also the

we but So adoption, When what -- at then will indications the really up the look look that, indication at clinician's to major ambulances. how look some widespread do with you even there again be And and assess the it you could into when really with get right is as -- you starts overall potentially couple the and the then market. reimbursement. hands. That that that drivers be we then

Operator

This to to Peter closing concludes for remarks. I question-and-answer over like session. any our turn conference the back Carlson would

Peter Carlson

your are events, number continued there the meetings. through you September certainly We XX, conference of York New City want H.C. everybody's let participation I in Wainwright for Spectral upcoming AI. and be interest in know to a appreciate available including do we will where X

also formal you, I'll we're interact say that, always, outside With to have us a available meeting thank As evening. the of good for and opportunities. with shareholders

Operator

attending has The concluded. now you conference presentation. Thank for today's

may disconnect. You now

Spectral AI (MDAI) 12 Aug 242024 Q2 Earnings call transcript